CClinicalTrials.gg
CompletedNCT03486249I-DISCOUpdated Mar 2, 2021

Interaction Diaphragm and Cardiac Function During Ventilator Weaning

An interventional study of Repetition of medical examinations performed as part of the care in Ventilator Weaning, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Weaning failure is associated with prolonged duration of mechanical ventilation that itself can worsen patient's prognosis. Therefore, identification of the causes and mechanisms leading to weaning failure is important in daily practice. While diaphragm dysfunction and pulmonary edema are two main causes of weaning failure, there are currently no data that quantify their respective contribution neither their potential co-existence. During weaning from mechanical ventilation, heart and lung interaction plays a major role. As a key factor, diaphragm function is therefore certainly involved in the occurrence of weaning-induced pulmonary edema. However, both phenomenons diaphragm dysfunction and weaning induced pulmonary edema have not been simultaneously investigated so far. This current project aims at exploring the relationship between diaphragm dysfunction and pulmonary in patients experiencing weaning failure. The objectives are 1) to quantify the respective contribution and co-existence of diaphragm dysfunction and weaning induced pulmonary edema and 2) to investigate the role of diaphragm function in the occurrence of weaning induced pulmonary edema.

Read the detailed description

The study will take place in the Medical ICU of Pitié-Salpêtrière Hospital in Paris. The ICU have an established and successful clinical research program and infrastructure.

ICU patients will be enrolled if eligible (based on inclusion and non inclusion criteria) after their first spontaneous breathing trial failure.

Diaphragm function will be assessed by its capacity to generate a pressure with the phrenic nerves stimulation technique (reference method) and by ultrasonography (thickening fraction). Weaning induced pulmonary edema will be diagnosed with cardiac echo and markers of plasma contraction (plasma protein concentration).

Phrenic nerves stimulation, diaphragm and cardiac ultrasound will be repeated as part of the research before the spontaneous breathing trial.

After obtaining consent and before starting the second spontaneous breathing trial, clinical and biological will be collected. EKG and maximal inspiratory pressure will be done. Then, a diaphragm ultrasound and cardiac echo will be done and the phrenic nerves stimulation method will be undertaken. After these measurements, the spontaneous breathing trial will start. At the end of the spontaneous breathing trial (30 minutes with pressure support 7 cmH2O and 0 positive end expiratory pressure) or sooner in case of intolerance (respiratory distress), a new cardiac echo and diaphragm ultrasound will be performed as part of standard care before resuming the initial ventilator settings. As recommended by the usual medical practice, a second phrenic nerves stimulation will be eventually done after resuming the initial ventilator settings.

Diaphragm capacity to generate pressure :

Twitch airway pressure (Ptr, stim) will be measured during phrenic nerve stimulation. Phrenic nerve stimulation will be performed by bilateral anterior magnetic stimulation.

Cardiac echo :

Cardiac echo will be performed with a Philips Sparq ultrasound with a dedicated probe. The following variables will be obtained: left ventricular ejection fraction, E wave, A wave, E' wave, TAPSE

Diaphragm ultrasound :

Diaphragm thickening fraction will be measured by placing 13 MHz transducer on the right chest wall in the ninth intercostal space mid-way between the anterior and mid-axillary line and held perpendicular to the chest wall. Thickening fraction will be computed as the percentage change in thickness between end-expiration (i.e. minimum muscle thickness) and peak inspiration (i.e. maximal muscle thickness) visualized in M-mode.

02

Conditions studied

  • Ventilator Weaning

Keywords

  • diaphragm dysfunction
  • ventilator weaning
  • pulmonary edema
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients adult (age ≥ 18 years)
  2. Intubation and invasive mechanical ventilation longer than 48 hours;
  3. Failure to the first spontaneous breathing trial;
  4. Presence of weaning readiness criteria
  5. Oral informed consent
  6. Patient with affiliation to the french healthcare system

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women
  2. Patient opposition
  3. Contraindication to perform magnetic phrenic nerves stimulation technique (chest tube, cardiac pacemaker or implanted defibrillator, cervical implants, chest drains,...)
  4. Impossibility to consider ventilator weaning (total ventilator dependence : preexisting neuromuscular disorders, cervical spine injury...)
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Patient difficult to wean

    Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.

    Other: Repetition of medical examinations performed as part of the care

Interventions

  • OtherRepetition of medical examinations performed as part of the care

    Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.

05

What researchers measure

Primary outcomes

  1. Failure at the spontaneous breathing trial

    Weaning failure defined by the criteria of the International Conference on Weaning (Boles et al. ERJ 2007)

    Time frame: During or at the end of the spontaneous breathing trial

Secondary outcomes

  1. Rate of patients with diaphragm dysfunction

    Diaphragm dysfunction will be defined as a decrease capacity of the diaphragm to generate a pressure

    Time frame: At the end of the patient participation (Day 3)

  2. Rate of patients with weaning induced pulmonary edema

    Weaning induced pulmonary edema will be defined by an increase in left filling pressure and/or plasma protides concentration

    Time frame: At the end of the patient participation (Day 3)

  3. Rate of patients with diaphragm dysfunction and weaning induced pulmonary edema

    Diaphragm dysfunction will be defined as a decrease capacity of the diaphragm to generate a pressure and weaning induced pulmonary edema will be defined by an increase in left filling pressure and/or plasma protides concentration

    Time frame: At the end of the patient participation (Day 3)

06

Study locations

1 site
  • Groupe Hospitalier Pitié-Salpétrière
    Paris, 75013, France
07

Registry details

Key details

Study ID
NCT03486249
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Apr 27, 2018
Primary completion
Apr 30, 2018
Completion
Jul 19, 2019
Last update
Mar 2, 2021

Study contacts

Martin DRES, MD, PhD
principal investigator · Assistance Publique Hoptiaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion